Literature DB >> 12486166

Nicotinic receptors mediate changes in spinal motoneuron development and axonal pathfinding in embryonic zebrafish exposed to nicotine.

Kurt R Svoboda1, Sukumar Vijayaraghavan, Robert L Tanguay.   

Abstract

We show that transient exposure of embryonic zebrafish to nicotine delays the development of secondary spinal motoneurons. Furthermore, there is a long-lasting alteration in axonal pathfinding in secondary motoneurons that is not ameliorated by drug withdrawal. These effects of nicotine were reversed by mammalian nicotinic receptor antagonists. Coupled with these changes is a long-term alteration in swimming behavior. Our results show that transient embryonic exposure to nicotine leads to long-lasting effects on the vertebrate nervous system. These results also demonstrate that the zebrafish is a useful model to examine the effects of nicotine specifically, and drugs of abuse in general, on the development of the CNS in vertebrates.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12486166      PMCID: PMC6758429     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  29 in total

1.  Glycine receptors regulate interneuron differentiation during spinal network development.

Authors:  Jonathan R McDearmid; Meijiang Liao; Pierre Drapeau
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-08       Impact factor: 11.205

Review 2.  Opportunities and challenges for using the zebrafish to study neuronal connectivity as an endpoint of developmental neurotoxicity.

Authors:  Galen W Miller; Vidya Chandrasekaran; Bianca Yaghoobi; Pamela J Lein
Journal:  Neurotoxicology       Date:  2018-04-25       Impact factor: 4.294

3.  Chlorpyrifos-oxon disrupts zebrafish axonal growth and motor behavior.

Authors:  Dongren Yang; Holly Lauridsen; Kalmia Buels; Lai-Har Chi; Jane La Du; Donald A Bruun; James R Olson; Robert L Tanguay; Pamela J Lein
Journal:  Toxicol Sci       Date:  2011-02-23       Impact factor: 4.849

4.  Teratogenic, bioenergetic, and behavioral effects of exposure to total particulate matter on early development of zebrafish (Danio rerio) are not mimicked by nicotine.

Authors:  Andrey Massarsky; Nishad Jayasundara; Jordan M Bailey; Anthony N Oliveri; Edward D Levin; G L Prasad; Richard T Di Giulio
Journal:  Neurotoxicol Teratol       Date:  2015-09-24       Impact factor: 3.763

5.  The cytisine derivatives, CC4 and CC26, reduce nicotine-induced conditioned place preference in zebrafish by acting on heteromeric neuronal nicotinic acetylcholine receptors.

Authors:  Luisa Ponzoni; Daniela Braida; Luca Pucci; Donzelli Andrea; Francesca Fasoli; Irene Manfredi; Roger L Papke; Clare Stokes; Giuseppe Cannazza; Francesco Clementi; Cecilia Gotti; Mariaelvina Sala
Journal:  Psychopharmacology (Berl)       Date:  2014-05-27       Impact factor: 4.530

6.  Gold nanoparticles disrupt zebrafish eye development and pigmentation.

Authors:  Ki-Tae Kim; Tatiana Zaikova; James E Hutchison; Robert L Tanguay
Journal:  Toxicol Sci       Date:  2013-04-02       Impact factor: 4.849

7.  The role of alpha7 and alpha4beta2 nicotinic receptors in the nicotine-induced anxiolytic effect in zebrafish.

Authors:  Zachary Bencan; Edward D Levin
Journal:  Physiol Behav       Date:  2008-07-12

8.  Uncoupling nicotine mediated motoneuron axonal pathfinding errors and muscle degeneration in zebrafish.

Authors:  Lillian Welsh; Robert L Tanguay; Kurt R Svoboda
Journal:  Toxicol Appl Pharmacol       Date:  2008-07-23       Impact factor: 4.219

9.  Embryonic motor activity and implications for regulating motoneuron axonal pathfinding in zebrafish.

Authors:  Evdokia Menelaou; Erin E Husbands; Robin G Pollet; Christopher A Coutts; Declan W Ali; Kurt R Svoboda
Journal:  Eur J Neurosci       Date:  2008-09       Impact factor: 3.386

10.  Secondary motoneurons in juvenile and adult zebrafish: axonal pathfinding errors caused by embryonic nicotine exposure.

Authors:  Evdokia Menelaou; Kurt R Svoboda
Journal:  J Comp Neurol       Date:  2009-01-20       Impact factor: 3.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.